RTTNews | Sep 5, 2021 10:57AM EDT

10:56 Sunday, September 5, 2021 (RTTNews.com) - Amgen (AMGN) said new data from the pivotal NAVIGATOR Phase 3 trial demonstrated that tezepelumab reduced exacerbations and improved lung function and nasal symptoms in patients with severe, uncontrolled asthma and comorbid nasal polyps.

Tezepelumab is a potential first-in-class treatment that acts at the top of the inflammatory cascade by targeting thymic stromal lymphopoietin (TSLP), an epithelial cytokine, and has the potential to treat a broad population of patients with severe asthma.

Tezepelumab is being developed by Amgen in collaboration with AstraZeneca.

The pre-specified exploratory analysis evaluated the effect of tezepelumab in NAVIGATOR patients with or without reported nasal polyps (NP+ or NP) in the past two years. The analysis showed tezepelumab achieved an 86% reduction in the annualized asthma exacerbation rate in NP+ patients and 52% in NP patients over 52 weeks, compared to placebo when added to standard of care.

Read the original article on RTTNews ( https://www.rttnews.com/3223314/amgen-s-tezepelumab-reduces-exacerbations-in-patients-with-severe-asthma-comorbid-nasal-polyps.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved